Vmbook Online ordering

Bio Path Holdings Inc

BioPath Holdings Inc (BPTH) is a biotechnology company focused on the development and commercialization of innovative targeted DNA cellular therapies for cancer. The company's lead product candidate, prexigebersen (BP1001), is a novel antisense DNA-based therapy for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

BioPath Holdings is a public company listed on the NASDAQ stock exchange under the ticker symbol BPTH. The company was founded in 2007 and is headquartered in Durham, North Carolina.

According to the most recent financial statements, as of September 30, 2021, BioPath Holdings had approximately $31.6 million in cash and cash equivalents. The company's net loss for the nine months ended September 30, 2021, was $11.2 million, compared to a net loss of $10.3 million for the same period in 2020.

BioPath Holdings' target market includes patients with AML and MDS, which are types of blood cancers that affect the bone marrow and lead to a decrease in the production of healthy blood cells. Prexigebersen has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AML and MDS, which provides BioPath Holdings with certain benefits, including seven years of market exclusivity if prexigebersen is approved by the FDA.

As of February 2023, the stock price of BioPath Holdings is trading at around $2.50 per share, with a market capitalization of approximately $32.8 million. The company has a relatively low trading volume, with an average of around 30,000 shares traded per day.

Investors who are considering investing in BioPath Holdings should be aware that biotechnology companies can be high-risk investments, as the development of new drugs is a complex and expensive process with a high failure rate. However, if successful, these companies can offer significant returns for investors. It is important for investors to conduct their own research and seek the advice of a financial advisor before making any investment decisions.